
RNTX Stock Forecast & Price Target
RNTX Analyst Ratings
Bulls say
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company with a focus on developing therapies for orphan pulmonary and fibrosis indications, featuring two Phase 2-ready clinical assets that address unmet medical needs. The successful increase of sRAGE levels in LTI-03 recipients by day 13 indicates promising pharmacodynamic activity, supporting the therapeutic potential of its pipeline candidates. Additionally, the company offers a favorable risk-reward opportunity, particularly if it can extend its cash runway, positioning itself to capitalize on significant market opportunities with few existing effective treatments.
Bears say
Rein Therapeutics Inc. has experienced a significant decline in stock value, with shares down 50% year-to-date in 2025, sharply contrasting with a modest 3.5% increase in the XBI index. This deterioration is primarily attributed to the company's decision to pause patient enrollments in the U.S., introducing a level of uncertainty that has negatively impacted investor confidence. Additionally, concerning data on lower sRAGE levels, which have been linked to poor survival rates in patients with Idiopathic Pulmonary Fibrosis, raises further doubts about the effectiveness of the company's therapeutic candidates in this indication.
This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RNTX Analyst Forecast & Price Prediction
Start investing in RNTX
Order type
Buy in
Order amount
Est. shares
0 shares